Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher - Should You Buy?

Key Points

• Shares rose ~6% to $3.55 on Friday, but trading volume was light at about 15,975 shares—roughly 46% below the average session volume.
• Analysts are split (one Buy, one Sell) resulting in an average rating of "Hold" and an average price target of $8.00, with D. Boral Capital issuing the $8 buy target and Weiss Ratings initiating coverage with a sell.
• Turn Therapeutics is a small-cap (~$105.8M) biotech that reported a loss (EPS -$0.09, P/E negative) and markets a proprietary PermaFusion™ platform designed to boost API bioavailability and reduce required dosages.

Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report)'s share price traded up 6% during trading on Friday . The stock traded as high as $3.55 and last traded at $3.55. 15,975 shares traded hands during mid-day trading, a decline of 46% from the average session volume of 29,635 shares. The stock had previously closed at $3.35.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TTRX. Weiss Ratings began coverage on Turn Therapeutics in a research report on Monday, January 5th. They set a "sell (e-)" rating for the company. D. Boral Capital reaffirmed a "buy" rating and issued a $8.00 price target on shares of Turn Therapeutics in a report on Tuesday, March 24th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Turn Therapeutics has an average rating of "Hold" and an average target price of $8.00.

Turn Therapeutics Trading Up 6.0%

The firm has a market capitalization of $105.75 million and a P/E ratio of -22.19. The business's 50 day simple moving average is $3.44.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.09) earnings per share for the quarter.

Institutional Investors Weigh In On Turn Therapeutics

A number of large investors have recently added to or reduced their stakes in TTRX. Hodges Capital Management Inc. bought a new position in Turn Therapeutics during the 4th quarter worth approximately $39,000. LPL Financial LLC purchased a new position in Turn Therapeutics during the 4th quarter valued at $51,000. Tamar Securities LLC bought a new position in Turn Therapeutics in the fourth quarter worth about $59,000. Composition Wealth LLC purchased a new position in shares of Turn Therapeutics during the 4th quarter worth approximately $63,000. Finally, Jane Street Group LLC purchased a new position in shares of Turn Therapeutics during the 4th quarter worth approximately $68,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.